2nd Edition of Cell & Gene Therapy World Conference(CGTWC) 2026

Scientific Sessions

Cell and Gene Therapy Pipeline Analysis

The global cell and gene therapy (CGT) pipeline is advancing at an unprecedented pace, transitioning rapidly from early discovery to late-stage clinical development and commercialization. This session will provide an in-depth overview of emerging therapeutic areas, with a particular focus on rare and orphan diseases where CGTs are demonstrating transformative potential. Discussions will highlight key molecules across clinical phases, strategic partnerships, and licensing activities shaping the global CGT landscape. In addition, experts will examine technology trends, innovation clusters, and intellectual property developments, offering strategic insights into how science, business, and regulation intersect to drive next-generation therapy pipelines.

Related Sessions

CRISPR Cas9 and Beyond: Emerging Genome Editing Platforms
Precision Genome Editing: From Target Discovery to Clinical Application
Engineering the Immune System: Gene and Cell Based Modulation
Non Viral Gene Delivery Strategies: Safety, Scalability, and Translation
Stem Cell Derived Therapeutics: iPSCs, Organoids and Tissue Engineering
Allogeneic vs Autologous Cell Therapies: Manufacturing, Efficacy, and Access
Manufacturing for Personalized Medicine: Customised Cell Products at Scale
Analytics, Potency Assays, and Rapid Release Strategies
CGTs for Monogenic Disorders: Delivering the Cure
Gene and Cell Therapies in Oncology: CAR T, NK, TCR, Oncolytic Approaches
Neurological and Neurodegenerative Disease Applications of CGTs
Market Access, Health Economics, and Reimbursement in CGT
Global Access and Equity: Bridging the CGT Innovation Gap
The Future Landscape of Cell and Gene Therapies: 2030 and Beyond
Cell and Gene Therapy Clinical Development
Cell and Gene Therapy Pipeline Analysis